Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Subcutaneous IGF-1 is not beneficial in 2-year ALS trial.

Literature DB >> 19029516

Subcutaneous IGF-1 is not beneficial in 2-year ALS trial.

E J Sorenson¹, A J Windbank, J N Mandrekar, W R Bamlet, S H Appel, C Armon, P E Barkhaus, P Bosch, K Boylan, W S David, E Feldman, J Glass, L Gutmann, J Katz, W King, C A Luciano, L F McCluskey, S Nash, D S Newman, R M Pascuzzi, E Pioro, L J Sams, S Scelsa, E P Simpson, S H Subramony, E Tiryaki, C A Thornton.

Abstract

BACKGROUND: Previous human clinical trials of insulin-like growth factor type I (IGF-1) in amyotrophic lateral sclerosis (ALS) have been inconsistent. This phase III, randomized, double-blind, placebo-controlled study was undertaken to address whether IGF-1 benefited patients with ALS.
METHODS: A total of 330 patients from 20 medical centers were randomized to receive 0.05 mg/kg body weight of human recombinant IGF-1 given subcutaneously twice daily or placebo for 2 years. The primary outcome measure was change in their manual muscle testing score. Secondary outcome measures included tracheostomy-free survival and rate of change in the revised ALS functional rating scale. Intention to treat analysis was used.
RESULTS: There was no difference between treatment groups in the primary or secondary outcome measures after the 2-year treatment period.
CONCLUSIONS: Insulin-like growth factor type I does not provide benefit for patients with amyotrophic lateral sclerosis.

Entities: Chemical Disease Gene Mutation Species

Mesh：

Substances：

Year: 2008 PMID： 19029516 PMCID： PMC2617770 DOI： 10.1212/01.wnl.0000335970.78664.36

Source DB: PubMed Journal: Neurology ISSN： 0028-3878 Impact factor: 9.910

19 in total

1. A comparison of muscle strength testing techniques in amyotrophic lateral sclerosis.

Authors:
Journal: Neurology Date: 2003-12-09 Impact factor: 9.910

2. Therapeutic benefit of intrathecal injection of insulin-like growth factor-1 in a mouse model of Amyotrophic Lateral Sclerosis.

Authors: Isao Nagano; Hristelina Ilieva; Mito Shiote; Tetsuro Murakami; Masataka Yokoyama; Mikio Shoji; Koji Abe
Journal: J Neurol Sci Date: 2005-08-15 Impact factor: 3.181

3. The ALSFRS-R: a revised ALS functional rating scale that incorporates assessments of respiratory function. BDNF ALS Study Group (Phase III).

Authors: J M Cedarbaum; N Stambler; E Malta; C Fuller; D Hilt; B Thurmond; A Nakanishi
Journal: J Neurol Sci Date: 1999-10-31 Impact factor: 3.181

Review 4. The insulin-like growth factor system and its pleiotropic functions in brain.

Authors: V C Russo; P D Gluckman; E L Feldman; G A Werther
Journal: Endocr Rev Date: 2005-08-30 Impact factor: 19.871

5. Preclinical testing of neuroprotective neurotrophic factors in a model of chronic motor neuron degeneration.

Authors: A M Corse; M M Bilak; S R Bilak; M Lehar; J D Rothstein; R W Kuncl
Journal: Neurobiol Dis Date: 1999-10 Impact factor: 5.996

6. Synergy of insulin-like growth factor-1 and exercise in amyotrophic lateral sclerosis.

Authors: Brian K Kaspar; Lindsay M Frost; Lindsey Christian; Priya Umapathi; Fred H Gage
Journal: Ann Neurol Date: 2005-05 Impact factor: 10.422

7. Venous thrombosis in an ALS population over four years.

Authors: L B Elman; A Siderowf; G Houseman; M Kelley; L F McCluskey
Journal: Amyotroph Lateral Scler Other Motor Neuron Disord Date: 2005-12

8. A randomized, placebo-controlled trial of topiramate in amyotrophic lateral sclerosis.

Authors: M E Cudkowicz; J M Shefner; D A Schoenfeld; R H Brown; H Johnson; M Qureshi; M Jacobs; J D Rothstein; S H Appel; R M Pascuzzi; T D Heiman-Patterson; P D Donofrio; W S David; J A Russell; R Tandan; E P Pioro; K J Felice; J Rosenfeld; R N Mandler; G M Sachs; W G Bradley; E M Raynor; G D Baquis; J M Belsh; S Novella; J Goldstein; J Hulihan
Journal: Neurology Date: 2003-08-26 Impact factor: 9.910

9. Nerve sprouting in innervated adult skeletal muscle induced by exposure to elevated levels of insulin-like growth factors.

Authors: P Caroni; P Grandes
Journal: J Cell Biol Date: 1990-04 Impact factor: 10.539

10. Muscle expression of a local Igf-1 isoform protects motor neurons in an ALS mouse model.

Authors: Gabriella Dobrowolny; Cristina Giacinti; Laura Pelosi; Carmine Nicoletti; Nadine Winn; Laura Barberi; Mario Molinaro; Nadia Rosenthal; Antonio Musarò
Journal: J Cell Biol Date: 2005-01-17 Impact factor: 10.539

80 in total

Review 1. Blood-Brain Barrier Driven Pharmacoresistance in Amyotrophic Lateral Sclerosis and Challenges for Effective Drug Therapies.

Authors: Loqman A Mohamed; Shashirekha Markandaiah; Silvia Bonanno; Piera Pasinelli; Davide Trotti
Journal: AAPS J Date: 2017-08-04 Impact factor: 4.009

Subcutaneous IGF-1 is not beneficial in 2-year ALS trial.

1. A comparison of muscle strength testing techniques in amyotrophic lateral sclerosis.

2. Therapeutic benefit of intrathecal injection of insulin-like growth factor-1 in a mouse model of Amyotrophic Lateral Sclerosis.

3. The ALSFRS-R: a revised ALS functional rating scale that incorporates assessments of respiratory function. BDNF ALS Study Group (Phase III).

Review 4. The insulin-like growth factor system and its pleiotropic functions in brain.

5. Preclinical testing of neuroprotective neurotrophic factors in a model of chronic motor neuron degeneration.

6. Synergy of insulin-like growth factor-1 and exercise in amyotrophic lateral sclerosis.

7. Venous thrombosis in an ALS population over four years.

8. A randomized, placebo-controlled trial of topiramate in amyotrophic lateral sclerosis.

9. Nerve sprouting in innervated adult skeletal muscle induced by exposure to elevated levels of insulin-like growth factors.

10. Muscle expression of a local Igf-1 isoform protects motor neurons in an ALS mouse model.

Review 1. Blood-Brain Barrier Driven Pharmacoresistance in Amyotrophic Lateral Sclerosis and Challenges for Effective Drug Therapies.

Review 2. How can we improve clinical trials in amyotrophic lateral sclerosis?

Review 3. Intraspinal stem cell transplantation for amyotrophic lateral sclerosis.

Review 4. The therapeutic potential of insulin-like growth factor-1 in central nervous system disorders.

5. Evidence-based drug treatment in amyotrophic lateral sclerosis and upcoming clinical trials.

Review 6. Motor neuron trophic factors: therapeutic use in ALS?

7. Estimating daily energy expenditure in individuals with amyotrophic lateral sclerosis.

8. The association between cancer and amyotrophic lateral sclerosis.

Review 9. Mesenchymal Stromal Cell Therapies for Neurodegenerative Diseases.

10. Moderate exercise delays the motor performance decline in a transgenic model of ALS.